Quantcast

Latest acute lymphoblastic leukemia Stories

2014-08-07 20:24:36

Leukotuximab is a novel, first-in-class Leukemia-specific mAb targeting JL-1 SHENYANG, China, Aug. 7, 2014 /PRNewswire/ -- 3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with DiNonA Inc. for the development, manufacturing and marketing of Leukotuximab, an anti JL-1 antibody for acute leukemia (AL), including acute myelocytic...

2014-07-10 12:30:41

WINDSOR, England, July 10, 2014 /PRNewswire/ -- Sigma Tau Pharma Ltd. (hereinafter referred to as Sigma-Tau Rare Disease), today announced the submission of an application to the European Medicines Agency (EMA) for use of its pegylatedL-asparaginase, Oncaspar(R) (pegaspargase) for the treatment of Acute Lymphoblastic Leukaemia (ALL) as part of a multi-agent chemotherapeutic regimen. (Logo: http://photos.prnewswire.com/prnh/20140710/696813 ) The submission is...

2014-07-07 12:29:12

- Designation supports the advancement of CTL019 to help address the unmet need of patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL) EAST HANOVER, N.J., July 7, 2014 /PRNewswire/ -- Novartis announced today that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy status to CTL019, an investigational chimeric antigen receptor (CAR) therapy for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic...

2014-07-01 08:29:55

Breakthrough Designation Reinforces Significant Unmet Need in the Treatment of This Highly Aggressive Cancer THOUSAND OAKS, Calif., July 1, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to investigational bispecific T cell engager (BiTE(®)) antibody blinatumomab, for adults with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL), a rapidly...

2014-06-27 12:26:33

Study published in Clinical Cancer Research and co-led by Adaptive Biotechnologies and the University of Washington demonstrates clinical utility of Next Generation Immune Profiling SEATTLE, June 27, 2014 /PRNewswire/ -- Adaptive Biotechnologies today announced results demonstrating enhanced accuracy and sensitivity of clonoSEQ in identifying risk of relapse in patients with B-cell Acute Lymphoblastic Leukemia (B-ALL), a childhood leukemia, compared to flow cytometry, the current...

2014-06-17 13:07:52

Walter and Eliza Hall Institute of Medical Research Melbourne researchers have shown a type of leukaemia can be successfully ‘reversed’ by coaxing the cancer cells back into normal development. The discovery was made using a model of B-progenitor acute lymphoblastic leukaemia (B-ALL), the most common cancer affecting children. Researchers from the Walter and Eliza Hall Institute showed that switching off a gene called Pax5 could cause cancer in a model of B-ALL, while restoring...

2014-06-02 16:25:22

Nonadherence Triples Relapse Risk, More Prevalent in African American and Asian Children WASHINGTON, June 2, 2014 /PRNewswire-USNewswire/ -- An estimated 25 percent of children in remission from acute lymphocytic leukemia (ALL) are missing too many doses of an essential maintenance medication that minimizes their risk of relapse, according to a study published online in Blood, the Journal of the American Society of Hematology (ASH). The study also reports that maintenance medication...

2014-05-07 08:32:14

First-in-class DOT1L Inhibitor in Clinical Development as Potential Personalized Therapeutic for Patients with Genetically Defined Acute Leukemias CAMBRIDGE, Mass., May 7, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced the initiation of a Phase 1b open-label clinical study of EPZ-5676 in pediatric patients with acute leukemias...

2014-04-30 08:31:42

PURIXAN(TM) (mercaptopurine) Oral Suspension Finally Makes Accurate Dosing Simple for Healthcare Professionals to Achieve--Especially with Children FRANKLIN, Tenn., April 30, 2014 /PRNewswire/ -- Rare Disease Therapeutics, Inc. (RDT), the producer of orphan pharmaceuticals for the treatment of rare diseases, announced today that they have received FDA approval for PURIXAN(TM) (mercaptopurine) 20 mg/mL oral suspension---a new, easier-to-dose, liquid form of an established treatment for...

2014-04-25 23:01:04

The acute lymphoblastic leukemia therapeutics market is segmented based on the existing regimens and drugs, pipeline drugs, and geography; http://www.marketsandmarkets.com/Market-Reports/acute-lymphocytic-leukemia-therapeutics-market-518.html. (PRWEB) April 26, 2014 The “Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - (Pipeline Forecast & Market Forecast in G8 Countries) (2010 - 2020)” analyzes and studies the major market drivers, restraints, and opportunities in...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related